Please use this identifier to cite or link to this item: http://repo.jfn.ac.lk/med/handle/701/2196
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRajasooriyar, C.-
dc.contributor.authorMoorthy, T.-
dc.contributor.authorRanatunge, N.-
dc.contributor.authorGinige, A.-
dc.contributor.authorSurenthirakumaran, R.-
dc.date.accessioned2020-12-14T10:07:04Z-
dc.date.accessioned2022-09-17T06:20:18Z-
dc.date.available2020-12-14T10:07:04Z-
dc.date.available2022-09-17T06:20:18Z-
dc.date.issued2020-
dc.identifier.citationProceedings JMA-September - 2020en_US
dc.identifier.urihttp://repo.jfn.ac.lk/med/handle/701/2196-
dc.language.isoenen_US
dc.publisherJaffna Medical Associationen_US
dc.subjectEsophageal canceren_US
dc.subjectTyrosine kinase inhibitorsen_US
dc.subjectMutationen_US
dc.titleSignificant incidence of braf p.V600E mutations in esophageal cancer sets the stage for potential use of tyrosine kinase inhibitorsen_US
dc.typeResearch abstracten_US
Appears in Collections:Community & Family Medicine

Files in This Item:
File Description SizeFormat 
OP14.pdf459.2 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.